Superparamagnetic Iron Oxide Nanoparticle-Aptamer Bioconjugates for Combined Prostate Cancer Imaging and Therapy

Superparamagnetic iron oxide nanoparticle-aptamer bioconjugates for combined prostate cancer imaging and therapy.

Over the past two decades, molecular targeted diagnostic and therapeutic agents have dramatically improved cancer diagnosis and treatment. Targeting allows the preferential delivery of therapeutic, diagnostic, or imaging agents to the intended site. Advances in nanotechnology have enabled the development of a variety of targeted nanoparticle platforms for diagnostic and therapeutic applications...

Nanoparticle-aptamer bioconjugates for cancer targeting.

The combination of targeted drug delivery and controlled-release technology may pave the road for more effective yet safer chemotherapeutic options for cancer therapy. Drug-encapsulated polymeric nanoparticle-aptamer bioconjugates represent an emerging technology that can facilitate the delivery of chemotherapeutics to primary and metastatic tumours. Aptamers are short nucleic acid molecules wi...

Drug-loaded superparamagnetic iron oxide nanoparticles for combined cancer imaging and therapy in vivo.

Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo.

Targeted uptake of therapeutic nanoparticles in a cell-, tissue-, or disease-specific manner represents a potentially powerful technology. Using prostate cancer as a model, we report docetaxel (Dtxl)-encapsulated nanoparticles formulated with biocompatible and biodegradable poly(D,L-lactic-co-glycolic acid)-block-poly(ethylene glycol) (PLGA-b-PEG) copolymer and surface functionalized with the A...

Aptamer-Nanoparticle Bioconjugates for Drug Delivery